Association of Interleukin 6 Inhibition With Ziltivekimab and the Neutrophil-Lymphocyte Ratio: A Secondary Analysis of the RESCUE Clinical Trial

IMPORTANCE: The neutrophil-lymphocyte ratio (NLR) independently predicts atherosclerotic events and is a potential biomarker for residual inflammatory risk. Interleukin (IL) 1β inhibition reduces the NLR, but whether inhibition of IL-6, a cytokine downstream of IL-1, also lowers the NLR is uncertain...

Descripción completa

Detalles Bibliográficos
Autores principales: Adamstein, Nicholas H., Cornel, Jan Hein, Davidson, Michael, Libby, Peter, de Remigis, Alessandra, Jensen, Camilla, Ekström, Kathrine, Ridker, Paul M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713672/
https://www.ncbi.nlm.nih.gov/pubmed/36449307
http://dx.doi.org/10.1001/jamacardio.2022.4277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713672/
https://www.ncbi.nlm.nih.gov/pubmed/36449307
http://dx.doi.org/10.1001/jamacardio.2022.4277

Ejemplares similares